Fernando Fernandes Paiva1, Maria Concepcion Garcia Otaduy2, Ricardo de Oliveira-Souza3, Jorge Moll4, Ivanei Edson Bramati5, Luciane Oliveira6, Andrea Silveira de Souza7, Fernanda Tovar-Moll7. 1. PhD, Magnetic Resonance Imaging and In Vivo Spectroscopy Center (CIERMag), Physics Institute of São Carlos, University of São Paulo, São Carlos SP, Brazil. 2. PhD, Magnetic Resonance Department, LIM44, InRad-Hospital das Clínicas, Faculty of Medicine of the University of São Paulo, São Paulo SP, Brazil. 3. PhD, Gaffreé e Guinle University Hospital, University of the State of Rio de Janeiro, Rio de Janeiro RJ, Brazil. D'Or Institute for Research and Education (IDOR), Rio de Janeiro RJ, Brazil. 4. PhD, D'Or Institute for Research and Education (IDOR), Rio de Janeiro RJ, Brazil. 5. D'Or Institute for Research and Education (IDOR), Rio de Janeiro RJ, Brazil. 6. MD, D'Or Institute for Research and Education (IDOR), Rio de Janeiro RJ, Brazil. 7. PhD, D'Or Institute for Research and Education (IDOR), Rio de Janeiro RJ, Brazil. Biomedical Sciences Institute, Federal University of Rio de Janeiro, Rio de Janeiro RJ, Brazil.
Abstract
Proton magnetic resonance spectroscopy (MRS) of the human brain has proven to be a useful technique in several neurological and psychiatric disorders and benefits from higher field scanners as signal intensity and spectral resolution are proportional to the magnetic field strength. OBJECTIVE: To investigate the effects of the magnetic field on the measurement of brain metabolites in a typical routine clinical setting. METHODS: Single voxel spectra were acquired from the posterior cingulate cortex in 26 healthy subjects. Each subject was scanned consecutively at 1.5T and 3.0T in a randomly distributed order. RESULTS: SNR and peak width improvements were observed at higher fields. However, SNR improvement was lower than the theoretical two-fold improvement. Other than the values obtained for creatine (Cre) and myo-Inositol (mI), which were both higher at 3.0T, all metabolite concentrations obtained were roughly the same at both field strengths. All the metabolite concentrations were estimated with a Cramer Rao lower bounds (CRLB) lower than 15% of the calculated concentrations. CONCLUSIONS: Even though the present study supports the expected benefits of higher field strength for MRS, there are several factors that can lead to different quantitative results when comparing 1.5T to 3.0T MRS. Future comparative studies are necessary to refine the metabolite thresholds for early detection and quantification of distinct neurological and psychiatric disorders using 3.0T MRS.
Proton magnetic resonance spectroscopy (MRS) of the human brain has proven to be a useful technique in several neurological and psychiatric disorders and benefits from higher field scanners as signal intensity and spectral resolution are proportional to the magnetic field strength. OBJECTIVE: To investigate the effects of the magnetic field on the measurement of brain metabolites in a typical routine clinical setting. METHODS: Single voxel spectra were acquired from the posterior cingulate cortex in 26 healthy subjects. Each subject was scanned consecutively at 1.5T and 3.0T in a randomly distributed order. RESULTS: SNR and peak width improvements were observed at higher fields. However, SNR improvement was lower than the theoretical two-fold improvement. Other than the values obtained for creatine (Cre) and myo-Inositol (mI), which were both higher at 3.0T, all metabolite concentrations obtained were roughly the same at both field strengths. All the metabolite concentrations were estimated with a Cramer Rao lower bounds (CRLB) lower than 15% of the calculated concentrations. CONCLUSIONS: Even though the present study supports the expected benefits of higher field strength for MRS, there are several factors that can lead to different quantitative results when comparing 1.5T to 3.0T MRS. Future comparative studies are necessary to refine the metabolite thresholds for early detection and quantification of distinct neurological and psychiatric disorders using 3.0T MRS.
Entities:
Keywords:
1.5T; 3.0T; brain; magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (MRS) has proven to be a useful non-invasive
technique to obtain information regarding the normal and abnormal neurochemistry of
the human brain.[1,2] In some clinical settings, MRS may show early
metabolic changes in apparently anatomically-normal tissue.[3] MRS benefits from higher field
scanners because signal intensity and spectral resolution (chemical shift) are
theoretically proportional to the strength of the magnetic field.[4,5] Another consequence is the increased J-coupling splitting. For
example, the metabolite myo-Inositol (mI) is represented as a
single peak at 3.56 ppm at 1.5T, while at 3.0T it appears to be split mainly into
two peaks at 3.56 and 3.64 ppm, making its visual detection and quantification
harder. Moreover, susceptibility effects are stronger at higher field strengths,
resulting in larger peak linewidths. Transverse relaxation times (T2) also tend to
decrease at higher fields, resulting in lower metabolite signals for a given echo
time (TE) when compared to lower field strengths. These higher-field effects may
have some clinical implications insofar altered levels of mI are associated with
prevalent neurological disorders, such as Alzheimer's disease.An accurate clinical interpretation of individual spectra requires the knowledge of
the normal range of relative metabolite levels (or absolute concentrations), as well
as an understanding of how the measured values depend on different aspects, such as
patient age, region of interest, metabolic conditions, specific MRS technique and
field strength. Even though some quantitative studies have been reported at
different field strengths,[6-9] most comparisons between the
widespread 1.5T and 3.0T systems, which are becoming increasingly common in clinical
settings, have focused on the evaluation of SNR and spectral resolution at higher
fields.[10] However, these
studies have not systematically compared the metabolite concentrations and ratio
estimates across different field strengths. Thus, quantitative comparisons between
both field strengths are needed in order to establish reference data at 3.0T as well
as to determine if the normal ranges previously established for 1.5T can be directly
adopted in any system. In the present study, metabolite levels at 1.5T and 3.0T were
assessed in healthy volunteers and the influence of field strength on the measured
values, and on calculated metabolite ratios used for diagnostic purposes, were
evaluated.
METHODS
1H MRS Methods. Healthy adult volunteers (N=26, seven males and nineteen
females, mean age 53±22 years) were scanned under an Institutional Review
Board (IRB)-approved protocol on a 3.0T Philips Achieva system equipped with
gradients capable of 80 mT/m amplitude and 200 mT/m/ms slew rate and on a 1.5T
Philips Gyroscan system equipped with gradients capable of 23 mT/m amplitude and 105
mT/m/ms slew rate (Philips Medical Systems, The Netherlands). All subjects were free
of neurological and neuropsychiatric disorders. A standard transmit body coil and an
eight-channel receive-only head coil were used for data acquisition in both systems.
Each subject was scanned consecutively at 1.5T and 3.0T in a randomly distributed
order, such that half of the volunteers were scanned initially on the 1.5T system
and the other half on the 3.0T system.At both field strengths, single voxel spectroscopy was performed using a
point-resolved spectroscopy sequence (PRESS). Before obtaining the spectra,
automatic shimming and water suppression were conducted by the scanner. At 1.5T,
spectra were acquired using the following parameters: TE=31 ms, TR=1500 ms, 512
spectral points and 1 kHz receiver bandwidth. At 3.0T, a TE=31 ms, TR=2000 ms, 2048
spectral points and 2 kHz receiver bandwidth was used. The repetition time was
optimized at both field strengths for optimal signal-to-noise ratio (SNR) for the
metabolites of interest. For each spectrum, a total of 128 measurements were
averaged at 1.5T and 96 measurements at 3.0T resulting in the same acquisition time
at both field strengths. In both cases, a voxel size of 25 x 25 x 25 mm3 positioned
using a T1- and a T2-weigthed scout image at the posterior cingulate gyrus and
aligned according to the parieto-occipital sulcus was used, as illustrated in Figure 1A.
Figure 1
[A] Schematic representation of the voxel location used for localized MRS
data acquisition, which is, due to chemical shift effects, a
representation of the voxel location of the NAA signal. [B] Typical
spectra obtained from a representative volunteer at 1.5T and 3.0T
showing the common brain metabolites.
[A] Schematic representation of the voxel location used for localized MRS
data acquisition, which is, due to chemical shift effects, a
representation of the voxel location of the NAA signal. [B] Typical
spectra obtained from a representative volunteer at 1.5T and 3.0T
showing the common brain metabolites.Data analysis and statistics. All spectroscopic data were processed
using LCModel.[11] An automatic
adjust of the phase and eddy current correction was applied to all spectra. Relative
metabolite concentrations and their uncertainties were estimated by fitting the
spectrum to a basis set of spectra acquired from individual metabolites in solution
and referencing to the unsuppressed water peak, and are expressed in institutional
units. Out of the basis set of spectra, a few metabolites and metabolite
combinations were selected for further analysis: N-acetylaspartate
and other N-acetyl-containing compounds (NAA), glutamine and
glutamate (Glx), creatine and phosphocreatine (Cre), choline-containing compounds
(Cho) and myo-Inositol (mI).Significant differences across the concentrations of the metabolites, accuracy of the
estimation through the analysis of the standard deviation of the estimated
metabolite, SNR, and full-width at half maximum (FWHM) obtained at both field
strengths, were tested using a non-parametric analysis (Wilcoxon signed-rank test)
performed with SPSS 16 (SPSS Inc., Chicago, IL, USA). All data are expressed as mean
and standard deviation and results were considered statistically significant when
p<0.05.
RESULTS
Figure 1A shows the voxel location used for data
acquisition, which is, given chemical shift effects, a representation of the voxel
location for the NAA signal. Figure 1B shows
typical spectra obtained from a representative volunteer at 1.5T and 3.0T. Results
show a better spectral resolution and SNR at 3.0T. This can be better visualized for
instance in the Glx region of the spectra where better resolved peaks at 3.0T are
evident compared to 1.5T.As expected, the averaged calculated SNR at 3.0T (23±6) was significantly
higher than the calculated value for 1.5T (15±4, p<0.0001). The linewidths
were also statistically different at the two field strengths (3.1±0.7Hz at
1.5T and 5.6±0.9 Hz at 3.0T, p<0.05).Figure 2A shows the average concentration of the
analyzed metabolites. All the metabolite concentrations were estimated with a Cramer
Rao lower bounds (CRLB) lower than 15% of the calculated concentrations and the mean
CRLB values obtained at 3.0T (2.8±0.5%, 2.3±0.5%, 4.4±0.8%,
5.2±0.9%, 9.5±2.0% for NAA, Cre, Cho, mI and Glx, respectively) were
statistically lower than their respective values at 1.5T (6.7±1.4%,
7.2±1.9%, 10.3±2.4%, 9.5±2.0%, 14.8±2.9% for NAA, Cre,
Cho, mI and Glx, respectively, p<0.001) for all metabolites. The mean
concentration obtained for NAA (6.3±0.8), Glx (7.2±1.5), and Cho
(1.0±0.2) at 1.5T were not statistically different from the values obtained
at 3.0T (6.6±0.7, 7.3±1.0, 0.9±0.1, respectively). However, the
values obtained for Cre and mI at 1.5T (4.8±0.4and 4.1±1.1,
respectively) were both lower than their respective values at 3.0T (5.6±0.3
and 4.8±0.7, respectively, p<0.005).
Figure 2
[A] Mean concentrations (in institutional units) of the analyzed
metabolites obtained at 1.5T and 3.0T; and [B] their respective ratios
related to Cre signal. Values are represented by mean and standard
deviation (N=26, *p<0.05, and
**p<0.005).
[A] Mean concentrations (in institutional units) of the analyzed
metabolites obtained at 1.5T and 3.0T; and [B] their respective ratios
related to Cre signal. Values are represented by mean and standard
deviation (N=26, *p<0.05, and
**p<0.005).Figure 2B shows the average metabolite ratios
for all volunteers. The ratios NAA/Cre, Cho/Cre, and Glx/Cre were lower at 3.0T
(1.19±0.12, 0.17±0.02and 1.31±0.19, respectively) compared to
their equivalent at 1.5T (1.33±0.16, 0.20±0.03and 1.52±0.29,
respectively, p<0.05). On the other hand, the mI/Cre ratio obtained at 1.5T
(0.86±0.24) was not statistically different to the value found at 3.0T
(0.86±0.09).
DISCUSSION
In the current study, brain metabolites detected at 1.5T and 3.0T in the same subject
were analyzed. As expected, when compared to the values obtained at 1.5T, spectra
obtained at 3.0T had higher SNR. However, the 53% increase found is well below the
theoretically predicted 100% improvement. The theoretical linear increase would be
expected by assuming constancy of [1] the noise generated by the system, [2] RF
penetration effects, [3] T1 and T2 relaxation times, none of which is actually
true.[12-16] Furthermore, an increase in the line-widths of the
metabolites at 3.0T was found that can partially counteract the SNR improvement
associated with higher field strength. The average value obtained at 1.5T was 3.1
Hz, while at 3.0T the value obtained was 5.6 Hz. This increase is in agreement with
previously published data,[10] but
is slightly less than the two-fold increase predicted by the theoretical relation of
susceptibility effects being proportional to field strength. This might be related
to the different shimming capabilities of the systems used, since only the 3.0T
scanner was equipped with second order shimming.Except for the values obtained for mI/Cre, all other metabolite ratios were smaller
at 3.0T. The lower values for NAA/Cre and Cho/Cre at 3.0T are likely to be due to
differences in transversal relaxation times for T2 at both field strengths. Spectra
were acquired using a TE of 31ms and a TR of 1500/2000ms, which means that they are
both T2- and T1-weighted. Thus, the signal intensities are related not only to
metabolite concentration, but also to its relaxation properties. Consequently,
metabolites with shorter T2 and longer T1 present lower signals, since the present
data were not corrected for relaxation effects.Based on the literature, expected relaxation effects can be estimated. For the
cingulate gyrus at 1.5T, a T2 of 351, 336 and 188 ms for Cho, NAA and Cre,
respectively, was previously reported,[17] whereas T2 for gray matter at 3.0T was significantly shorter:
209, 216 and 131 ms for Cho, NAA and Cre, respectively.[18] Thus, the shortening ratio of T2 at a higher field
is different for each metabolite, which could explain the different metabolite
ratios obtained at 3.0T compared to 1.5T. Furthermore, absolute metabolite
concentrations were obtained by comparing metabolite signal intensity to water
signal of an unsuppressed reference scan. Hence, in the evaluation of these absolute
values the manner in which T2 and T1 of water changes with increasing field has to
be taken into account. In the literature, there are reports of T2 of water brain
tissue of around 107 ms at 1.5T and around 60 ms at 3.0T.[19,20] T2 of
cerebral spinal fluid (CSF) is much longer where values greater than 1s at 1.5T, and
around 500 ms at 3.0T, having been reported.[20,21] Thus, the
significant higher absolute values for Cre and mI at 3.0T and a trend toward higher
values for NAA at 3.0T might be related to a stronger T2 shortening of the water
signal at 3.0T as compared to these metabolites. Changes in T1 can also partially
contribute to the observed differences. However, the longer TR employed at 3.0T
acquisition should compensate for the effects caused by longer T1 at 3.0T. Also, it
has been reported that T1 changes with field strength increases are less
prominent.[15,22-25]In the particular case of mI, the analysis is more complicated due to its coupled
resonance, around 3.56 ppm. The mI signal arises from six CH groups which generate a
complex spectral pattern and are responsible for its intrinsic low SNR in the proton
MRS. In addition, its spectra overlaps with a number of other brain metabolites,
including Cho, Glx, glycine (Gly), taurine (Tau), and macromolecules,[26] which introduce uncertainty in the
estimation process and increase the within-subject variability.[27,28] As the field strength increases, the higher spectral
resolution allows better separation of the mI resonances. As the relaxation time of
the overlapping metabolites changes, the appearance of the mI spectra also changes
at different field strengths. Thus, an accurate estimation of mI concentration
requires the quantification of all of its resonances, which should be less
challenging at higher field strengths. Indeed, the CRLB of mI at 3.0T are lower than
at 1.5T.The overall smaller CRLB obtained in the estimation of the metabolite concentrations
at 3.0T demonstrate an important advantage of working at a higher magnetic field.
This likely reflects the positive effects of the higher SNR and spectral resolution
accomplished at higher fields. In addition, there was a trend for smaller variations
between subjects in the metabolite quantification at higher field strength. This is
also an interesting factor for clinical applications, in which pathological
thresholds are established on the basis of group analyses.The present study was performed using systems with equivalent implementation of PRESS
pulse sequence and equivalent head coils. This is an advantage when compared to
previous studies[10] because
accurate reproducibility of spectroscopic data depends on the efficiency of the
pulse sequence used for spatial localization. This is especially important when
comparing spectroscopic data acquired at different field strengths. In spite of
this, small effects caused by differences in the individual optimization phase of
the sequence parameters, such as water suppression and flip angle calibration,
cannot be ruled out.In conclusion, even though the theoretically predicted 100% improvement in SNR and
spectral resolution cannot be achieved in practice, the benefits of higher field
strengths for MRS are clear. However, due to the number of factors that can bias
comparisons between field strengths, further quantitative studies at 3.0T are needed
in order to redefine the normal statistical threshold for different metabolites and
brain locations. Such normative studies will be crucial to improve the value of MRS
as a clinical tool for diagnosis and follow-up of several neurological and
psychiatric disorders.